Catheter Precision Announces Launch of LockeT in Switzerland

Rhea-AI Summary

Catheter Precision (NYSE/American: VTAK) announced the commercial launch of its LockeT suture retention device in Switzerland on December 1, 2025. The first clinical cases were performed at Spitalzentrum Biel under PD Dr. Rainer Zbinden with reported excellent procedural outcomes and positive staff feedback.

The launch follows a strategic distribution agreement with FuMedica AG, enabling rollout to hospitals and clinics across Switzerland and expanding Catheter Precision’s European footprint. The company noted over 10,000 LockeT units shipped globally and highlighted benefits including reduced groin management costs and support for same-day discharge.

Positive

• Signed distribution agreement with FuMedica AG to cover Switzerland
• First clinical cases at Spitalzentrum Biel reported excellent procedural outcomes
• 10,000+ LockeT units shipped globally, indicating existing commercial traction
• Potential same-day discharge and reduced groin management costs noted

Negative

• None.

Fort Mill, SC, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market today announced the successful launch of its LockeT suture retention device in Switzerland.

The first clinical cases were performed at Spitalzentrum Biel, led by PD Dr. Rainer Zbinden, with excellent procedural outcomes and positive feedback from both the clinical and nursing teams. This milestone follows the company’s recent strategic distribution agreement with FuMedica AG, a premier Swiss medical device distributor with a strong presence in cardiovascular and interventional medicine. The partnership enables the introduction of LockeT to hospitals and clinics across Switzerland, further expanding Catheter Precision’s European footprint.

Fatih Ayoglu, Sales Manager EMEA & APAC at Catheter Precision, said, “We’ve recently partnered with FuMedica to distribute LockeT in Switzerland, and it’s already exciting to see the first cases roll out so quickly. LockeT is intuitive and easy to use—it reduces groin management costs and supports same-day discharge. With over 10,000 LockeTs shipped globally, we’re growing fast and working hard with our partners, one patient at a time.”

About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval.

About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words.  These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.

The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

# # #

CONTACTS:

Investor Relations
973-691-2000
IR@catheterprecision.com

FAQ

What did Catheter Precision (VTAK) announce on December 1, 2025 about LockeT in Switzerland?

Catheter Precision announced the launch of LockeT in Switzerland and a distribution agreement with FuMedica AG, with first clinical cases performed at Spitalzentrum Biel.

How will the FuMedica AG distribution agreement affect Catheter Precision (VTAK) in Europe?

The agreement enables introduction of LockeT to hospitals and clinics across Switzerland, expanding the company’s European footprint.

What clinical results were reported for LockeT's first Swiss cases reported December 1, 2025?

First cases at Spitalzentrum Biel led by PD Dr. Rainer Zbinden reported excellent procedural outcomes and positive clinical and nursing feedback.

How many LockeT units has Catheter Precision (VTAK) shipped globally as of this announcement?

The company reported over 10,000 LockeT units shipped globally.

What operational benefits does LockeT claim to provide for patients and hospitals?

Management noted LockeT is intuitive, may reduce groin management costs, and can support same-day discharge.